These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 38196277

  • 21. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K.
    BMC Cancer; 2019 Oct 15; 19(1):954. PubMed ID: 31615466
    [Abstract] [Full Text] [Related]

  • 22. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Xu HF, Gao QZ, Yang RJ.
    Immunotherapy; 2021 Dec 15; 13(17):1395-1405. PubMed ID: 34607482
    [Abstract] [Full Text] [Related]

  • 23. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Waki K, Tsuji K, Kohno H, Kohno H, Moriya T, Chayama K.
    J Dig Dis; 2015 Sep 15; 16(9):505-12. PubMed ID: 26121102
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y, Zhang H, Xu H, Wang Y, Feng L, Yi F.
    World J Surg Oncol; 2024 May 06; 22(1):122. PubMed ID: 38711095
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y, Mei J, Chen J, Zhang D, Wang J, Wang X, Yi M, Zhou Z, Zhang Y, Chen M, Guo R, Xu L.
    Ann Surg Oncol; 2022 Mar 06; 29(3):2016-2029. PubMed ID: 34637058
    [Abstract] [Full Text] [Related]

  • 28. Advanced hepatocellular carcinoma with major portal vein invasion: Therapeutic outcomes of hepatic arterial infusion chemotherapy vs concurrent radiotherapy.
    Chiang CL, Liang HL, Chang KC, Tsai WL, Yu HC, Lin KH, Li MF.
    J Chin Med Assoc; 2024 Feb 01; 87(2):171-178. PubMed ID: 38099672
    [Abstract] [Full Text] [Related]

  • 29. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK.
    J Cancer Res Clin Oncol; 2021 Oct 01; 147(10):3123-3133. PubMed ID: 33893539
    [Abstract] [Full Text] [Related]

  • 30. Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.
    Wang W, Li R, Li H, Wang M, Wang J, Wang X, Zhou Q.
    Immunotargets Ther; 2024 Oct 01; 13():399-412. PubMed ID: 39184311
    [Abstract] [Full Text] [Related]

  • 31. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K, Watanabe M, Ikehara T, Kogame M, Matsui T, Okano N, Kikuchi Y, Nagai H, Ishii K, Makino H, Igarashi Y, Sumino Y.
    Hepatogastroenterology; 2014 Jun 01; 61(132):885-91. PubMed ID: 26158136
    [Abstract] [Full Text] [Related]

  • 32. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X, Li X, Sun P, Li Z, Sun P, Ning S.
    BMC Cancer; 2024 Apr 16; 24(1):480. PubMed ID: 38627684
    [Abstract] [Full Text] [Related]

  • 33. One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
    Lai Z, Huang Y, Wen D, Lin X, Kan A, Li Q, Wei W, Chen M, Xu L, He M, Shi M.
    BMC Med; 2022 Oct 31; 20(1):415. PubMed ID: 36310160
    [Abstract] [Full Text] [Related]

  • 34. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
    Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, Kim YS, Yim HJ, Um SH, Chung WJ, Hwang JS, Cho SB, Eun JR.
    Cancer Chemother Pharmacol; 2015 Apr 31; 75(4):739-46. PubMed ID: 25663125
    [Abstract] [Full Text] [Related]

  • 35. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study.
    Chen S, Yuan B, Yu W, Wang X, He C, Chen C.
    J Surg Oncol; 2022 Dec 31; 126(7):1205-1214. PubMed ID: 35856502
    [Abstract] [Full Text] [Related]

  • 36. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, Xu L, Zheng K, Li W, Xing B, Wang X.
    Cardiovasc Intervent Radiol; 2020 Jul 31; 43(7):996-1005. PubMed ID: 31974744
    [Abstract] [Full Text] [Related]

  • 37. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
    Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim YJ.
    Asia Pac J Clin Oncol; 2012 Jun 31; 8(2):164-71. PubMed ID: 22524575
    [Abstract] [Full Text] [Related]

  • 38. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L, Wang C, You R, Leng B, Yu Z, Xu Q, Cheng Y, Yin G.
    J Gastroenterol Hepatol; 2024 Apr 31; 39(4):746-753. PubMed ID: 38240156
    [Abstract] [Full Text] [Related]

  • 39. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M.
    J Clin Oncol; 2022 Jan 10; 40(2):150-160. PubMed ID: 34648352
    [Abstract] [Full Text] [Related]

  • 40. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH, Lee DS, Cho CW, Yun SS.
    World J Surg Oncol; 2019 Aug 15; 17(1):143. PubMed ID: 31416447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.